Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

50 results about "Progenitor" patented technology

In genealogy, the progenitor (rarer: primogenitor; German: Stammvater or Ahnherr) is the – sometimes legendary – founder of a family, line of descent, clan or tribe, noble house or people group. Genealogy (commonly known as family history) understands a progenitor to be the earliest recorded ancestor of a consanguineous family group of descendants.

Method for directionally differentiating iPSC into iNK

The invention relates to the technical field of cell differentiation, in particular to a method for directionally differentiating iPSC into iNK. Specifically, the method for preparing the CD34 + hematopoietic stem / progenitor cell and the iNK on the shaking table comprises the following steps: forming an embryoid (EB) by the iPSC on the shaking table, and then collecting a single cell supernatant to obtain the iNK. According to the method, high-proportion CD34 < + > hematopoietic stem / progenitor cells are obtained by adjusting the factor concentration and collecting the supernatant and are further induced and differentiated into the iNK, and more than 100 iNKs can be harvested before amplification of one iPSC according to the iNK harvested in batches.
Owner:SUZHOU EXCELL BIOLOGICAL TECH CO LTD

Expression vector structure and method for producing multilineage hematopoietic stem / progenitor cells

The invention relates to the technical field of biology, in particular to an expression vector structure and a method for generating multilineage hematopoietic stem / progenitor cells based on an expression vector. The cDNA sequences of hnCD16 and mbIL-15 are expressed in the same vector in series and integrated into a mammal pluripotent stem cell genome, the pluripotent stem cell capable of stably expressing hnCD16 and mbIL-15 can be obtained, the method is easy and convenient to operate and high in efficiency, hematopoietic stem / progenitor cells capable of expressing mbIL-15-hnCD16 can be obtained through induced differentiation, and the hematopoietic stem / progenitor cells can be used for preparing the hematopoietic stem / progenitor cells. And the mbIL-15-hnCD16-NK cell obtained by further induced differentiation has higher killing activity and longer survival time.
Owner:BEIJING JINGKE XINTUO BIOTECHNOLOGY CO LTD

Compositions comprising isolated endothelial progenitor cells and uses thereof

The present technology comprises isolated endothelial progenitor cell (EPC) populations comprising PROCR+ / - PDGFRA+ / - EPCs and mesenchymal stem cell (MSC) populations, and methods of making and use thereof in treating hypoxic-ischemic encephalopathy (HIE) or brain injury in a subject.
Owner:THE UNIVERSITY OF QUEENSLAND

Methods of generating a population of neurons from human glial progenitor cells and genetic constructs for carrying out such methods

The present disclosure is directed to a method of generating a population of neurons. This method involves providing a population of human glial progenitor cells: providing a recombinant genetic construct comprising (i) a promoter and / or enhancer for a gene which is selectively or specifically expressed by human glial progenitor cells, and (ii) a nucleic acid sequence encoding one or more neuronal reprogramming factors for producing neurons from glial progenitor cells, where the nucleic acid sequence is operably linked to the 3′ end of said promoter and / or enhancer to achieve expression of the one or more neuronal reprogramming factors; transfecting cells of the glial progenitor cell population with the recombinant genetic construct; and culturing the population after said transfecting under conditions suitable for neuron production from the transfected glial progenitor cells of the population. Also disclosed are methods of inducing the production of neurons, as well as recombinant genetic constructs.
Owner:UNIVERSITY OF ROCHESTER

Treatment of liver failure using personalized progenitor cells and derivatives thereof

PCT designated stage expiredWO2025117474A1HepatocytesUnknown materialsProgenitorAdjuvant
Methods and compositions of matter useful for preventing or reversing liver failure. Autologous hepatic progenitors are generated from pluripotent stem cells and administered in a manner to augment and / or replace endogenous regenerative processes. Generation of "adjuvant cells" to enhance engraftment and function of hepatic progenitors. Compositions and methods of reversing liver fibrosis whether caused by viral or chemical toxicity.
Owner:IMMORTA BIO INC

SgRNA targeting plagl1 gene dmr, epigenetic editing system and application thereof

PendingCN122445641AProgenitorEpigenetic Profile
The present application relates to a kind of sgRNA targeting Plagl1 gene DMR, epigenetic editing system and its application.Specifically, the present application provides sgRNA targeting Plagl1 gene differential methylation region, which forms epigenetic editing system with dCas9-Tet1-CD fusion protein.The system is loaded in injectable type light-cured silk fibroin hydrogel, the expression of Plagl1 gene in periosteum stem / progenitor cells is accurately activated by targeted demethylation modification, thereby promoting osteogenic differentiation.The present application combines epigenetic regulation with biomaterial delivery, and provides a safe, efficient new strategy for jaw bone defect regeneration and repair.
Owner:SHANGHAI STOMATOLOGICAL HOSPITAL FUDAN UNIV

Cells and methods of uses and making the same

To provide genetically engineered stem cells, plasma cells, and B cells for avoiding immune rejection within a host, and methods of making the same and uses thereof.SOLUTION: Provided is a method of differentiating human embryonic stem cells (ES cells) into plasma cells, the method comprising producing precursor cells and differentiating the precursor cells into B cells.SELECTED DRAWING: Figure 10
Owner:UNIV OF WASHINGTON

Application of Gemin8 or Rnpc3 in maintaining protein homeostasis in hematopoietic stem and progenitor cells

The present invention discloses the application of Gemin8 or Rnpc3 in maintaining protein homeostasis in hematopoietic stem and progenitor cells. The present invention creatively discovers for the first time the new use of Gemin8 or Rnpc3 in maintaining protein homeostasis in hematopoietic stem and progenitor cells, effectively overcoming the current technical problem faced in this field of how to effectively maintain protein homeostasis in hematopoietic stem and progenitor cells, and provides an effective method for maintaining protein homeostasis in hematopoietic stem and progenitor cells. It also lays the foundation for the development of hematopoietic stem and progenitor cells with better functionality and transplantation potential, and has broad application prospects.
Owner:INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES

Method for identifying dopaminergic neurons and progenitor cells

This provides a molecular diagnostic tool useful for the efficient and accurate characterization of the discriminative and functional properties of iPSC-derived dopaminergic neurons. [Solution] A computer-based method for identifying determined dopaminergic progenitor cells within an in vitro population of neural progenitor cells is provided, comprising: receiving a test dataset containing data such as gene expression profile information relating to an in vitro population of neural progenitor cells; querying a gene expression reference database and comparing the test dataset with the gene expression reference database, wherein the gene expression reference database contains gene expression profile information of the desired determined dopaminergic progenitor cells; and outputting a computer-calculated label classification that includes an indication of whether or not the in vitro population of neural progenitor cells contains the determined dopaminergic progenitor cells.
Owner:THE SCRIPPS RES INST +1

Human otic progenitor identification and isolation

The present invention relates generally to the identification and isolation of human otic progenitor cells. More specifically, the present invention relates to a method of using cell markers to identify and isolate human otic progenitor cells from a mixed population of cells, methods of enrichment and production of human otic progenitor cells, and associated kits for use in identification and / or isolation of human otic progenitor cells, wherein the cell markers are selected from SSEA1 (CD15), disialoganglioside GD3, TRA-2-49 (liver / bone / kidney alkaline phosphatase), SSEA4, ganglioside GD2 and CD141.
Owner:UNIV OF SHEFFIELD

In-vitro preparation method for midbrain dopaminergic progenitor cell population

Provided is a method for differentiating pluripotent stem cells in vitro to prepare a cell population mainly composed of midbrain floor plate dopaminergic progenitor cells, wherein the progenitor cells can efficiently and directionally differentiate into midbrain dopaminergic neuron precursors and midbrain dopaminergic neurons after being transplanted into a subject. Further provided is a cell population prepared by the method, a pharmaceutical composition containing the cell population, and a method for using the cell population or the pharmaceutical composition to treat or ameliorate a neurological disorder caused by a reduction in the number of midbrain dopaminergic neurons and / or impairment of function thereof.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI +1

Methods for isolating neural stem and progenitor cells from the developing human brain

Methods for identifying, isolating and enriching neural stem and progenitor cells (NSPC) such as ventricular radial glia, outer radial glia, astrocytes, pre-oligodendrocyte precursor cells, oligodendrocyte precursor cells, oligodendrocytes, early excitatory neurons, late excitatory neurons, bipotent glial progenitors, and inhibitory neurons are provided. These methods find use in transplantation, to eliminate specific cell subsets, for experimental evaluation, as a source of lineage and cell-specific products, and the like, for example for use in treating human disorders of the central nervous system (CNS).
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Haematopoietic stem / progenitor cells and methods for their production

The invention relates to differentiating a pluripotent stem cell (PSC) into a definitive haematopoietic stem / progenitor cell which is capable of multilineage engraftment, and to therapeutic uses of such haematopoietic stem / progenitor cells.
Owner:MURDOCH CHILDRENS RES INST

A marker for evaluating or assisting in the evaluation of the identity and senescence of over-proliferated progenitor cells in the subventricular region.

This invention discloses a marker for evaluating or assisting in the evaluation of the identity and senescence of hyperplastic progenitor cells in the subventricular zone (SVZ). Through constructing and analyzing neural stem cell sequencing libraries and immunofluorescence assays of the SVZ region in mice of different ages, this invention found that HMGB2 can be used as a marker to identify or assist in the identification of hyperplastic progenitor cells in the SVZ; UBE2C can be used as a marker to further distinguish hyperplastic progenitor cells in SVZs with active and inactive cell cycles; and APOE can be used as a marker to further distinguish hyperplastic progenitor cells in SVZs derived from senescent and young animals.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI

Method for producing neural progenitor cells derived from induced pluripotent stem cells

The present invention relates to a method for producing neural progenitor cells. The method for producing neural progenitor cells according to an aspect ensures reproducibility by setting criteria for each step, uniformly performs differentiation across production batches, and enables mass production of high-purity neural progenitor cells by removing unspecified types of cells other than neural progenitor cells using culture methods and culture conditions.
Owner:IPS BIO INC

Method for producing cell aggregate including glial progenitor cells

The method for producing a cell aggregate including glial progenitor cells according to the present invention comprises:(1) a step of subjecting pluripotent stem cells to suspension culture in an embryoid-body-forming culture medium containing one or more SMAD signaling inhibitors and one or more Wnt signaling activators in the absence of feeder cells for 5 days to 10 days, to form a cell aggregate;(2) a step of subjecting the cell aggregate obtained in (1) to suspension culture in an embryoid-body-forming culture medium containing retinoic acid;(3) a step of subjecting the cell aggregate obtained in (2) to suspension culture in an embryoid-body-forming culture medium or neuron-and-glia-proliferating culture medium containing retinoic acid and one or more SHH signaling activators; and(4) a step of subjecting the cell aggregate obtained in (3) to suspension culture in a neuron-and-glia-proliferating culture medium containing no retinoic acid and one or more SHH signaling activators.
Owner:RACTHERA CO LTD +1

Improved production of induced mesencephalic dopaminergic progenitor cells from pluripotent stem cells

PendingCN122341721AProgenitorMidbrain
This disclosure relates to a method for producing induced midbrain dopaminergic progenitor cells (imDAPs) that can provide high imDAP cell differentiation efficiency. This disclosure also provides a substantially homogeneous imDAP cell population.
Owner:ANHUI ZHONGSHENG TRACEABLE BIOTECHNOLOGY CO LTD

Method of differentiating neural cells and related compositions and methods of use

To provide methods of lineage specific differentiation of pluripotent stem cells, including induced pluripotent stem cells, into floor plate midbrain progenitor cells, determined dopamine (DA) neuron progenitor cells, and / or DA neurons.SOLUTION: Provided is a method of differentiating neural cells, the method comprising: (a) performing a first incubation comprising culturing pluripotent stem cells in a non-adherent culture vessel under conditions to produce a cellular spheroid; and (b) performing a second incubation comprising culturing cells of the spheroid in a substrate-coated culture vessel under conditions to neurally differentiate the cells.SELECTED DRAWING: Figure 1
Owner:ASPEN NEUROSCIENCE INC

Improved production of induced midbrain dopaminergic progenitor cells from pluripotent stem cells

PCT designated stage expiredWO2025091318A1Culture processNervous system cellsProgenitorMidbrain
The present disclosure is directed to a method of producing induced midbrain dopaminergic progenitor (imDAP) cells which can provide high efficiency for differentiation of imDAP cells. The present disclosure also provides a substantially homogeneous population of imDAP cells.
Owner:NUWACELL BIOTECHNOLOGIES CO LTD

Amino acid composition and use thereof

The present disclosure provides compositions and methods for promoting stem cell and / or progenitor cell proliferation and / or differentiation. The compositions provided can be used to treat diseases or conditions such as wound healing associated with mucosal barrier function in subjects in need, treat skin disorders (e.g., atopic dermatitis, psoriasis, bedsores or conditions associated with skin aging), treat pulmonary disorders (e.g., asthma), conditions associated with improving mucosal barrier function and / or treat GI mucosal damage. The present disclosure also provides methods for promoting the proliferation and / or differentiation of stem cells and / or progenitor cells in subjects in need of such treatment by administering compositions. The ability to stimulate the proliferation and / or differentiation of stem cells and / or progenitor cells in vivo, in vitro and / or in vitro provides great benefits. The present disclosure can be used to increase stem cell populations in vivo, in vitro and / or in vitro. Stem cell transplantation provides treatment and / or cure for many disease states, degeneration and / or damage.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC +1

Engineered progenitor cells and methods of use

Disclosed herein are engineered progenitor cells and methods of using the same. Also disclosed herein are engineered cells differentiated from engineered progenitor cells of the present disclosure. Also disclosed herein are methods of treating a condition in a subject by administering an engineered progenitor cell or an engineered cell differentiated from an engineered progenitor cell of the present disclosure.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)

Methods for producing fibroadipogenic progenitor cells

The present disclosure provides methods of producing a preparation of fibroadipogenic progenitors (FAPs) from a cell mixture. In certain embodiments, the present disclosure provides a method of producing a preparation of human FAPs from a skeletal muscle biopsy sample for later use.
Owner:REGENTS OF THE UNIVERSITY OF MINNESOTA

Use of t-5224 in the expansion and / or functional enhancement of human circulating hematopoietic stem / progenitor cells

This invention provides the application of T-5224 in the expansion and / or functional enhancement of human circulating hematopoietic stem / progenitor cells, relating to the fields of stem cell biology and regenerative medicine. It is the first time T-5224 has been applied to the expansion of cHSPCs, opening up a new pathway to improve stem cell culture efficacy by regulating downstream transcriptional hubs of inflammatory / stress signals. Accompanied by the upregulation of HOXB4 gene expression, it significantly improves LIN... ‑ CD45RA ‑ CD34 + CD38 low / ‑ The cell expansion factor, maintaining cell stemness and regeneration capacity, provides a new approach to solving the technical problem of the difficulty in rapidly expanding human circulating hematopoietic stem / progenitor cells in in vitro culture while maintaining cell stemness and regeneration potential.
Owner:THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE +1

Production of conditional, phenotype-restricted hypoimmune progenitor cells

PCT designated stageWO2026178009A1ProgenitorCell biology
The present disclosure relates to recombinant nucleic acid molecules and related methods for production of conditional, phenotype-restricted hypoimmune progenitor cells.
Owner:UNIVERSITY OF ROCHESTER

Mesenchymal progenitor cells for enhancing partial reprogramming of target cells

Provided herein are methods and related compositions for enhancing partial reprogramming of target cells in a subject in need thereof (e.g., a human subject suffering from or at risk of suffering from a disease), the methods comprising administering to the subject a plurality of mesenchymal mass spectrum progenitor cells or stem cells (MLPSC), exosomes derived therefrom, or conditioned media derived therefrom, the subject expresses or will express one or more reprogramming factors in a population of target cells, thereby causing a plurality of the target cells in the subject to be partially reprogrammed but not fully reprogrammed.
Owner:MESOBLAST INTERNATIONAL SARL

Method for generating T cell lineage populations from stem / progenitor cells

The present disclosure provides a method for generating a T cell lineage population from progenitor T cells. The method comprises culturing the progenitor cells in the presence of Notch signalling ligand, such as Delta-like-4 (DL4), provided on a surface area of at least 7 square centimetres per millilitre culture volume (7 cm2 / mL). Population of cells produced using the method are provided as well as methods of using same. Further provided is a method of differentiating a progenitor T cell population enriched for CD4−CD8+ TCRγδ+ cells comprising culturing progenitor T cells in the presence of Notch signalling ligand, such as DL4, provided on a surface area of 0.78 to 4.7 cm2 / mL.
Owner:NOTCH THERAPEUTICS (CANADA) INC +1

Health care device and use thereof

A health care device and an use thereof are configured to transmit a low frequency wave to a spine or navel to increase the number of endothelial progenitor cells (EPC) and to reduce the number of the circulating endothelial cells (CEC), which may reduce the risk of cardiovascular-related adverse diseases. The health care device includes a box body, a power supply, a speed controller, a rotating mechanism, a linkage mechanism, a knocker and a conical table. The power supply is electrically connected to the speed controller to output electricity to the speed controller. The speed controller is electrically connected to the rotating mechanism and controls the rotating mechanism to rotate at a predetermined speed. The rotating mechanism is connected to the knocker to drive the knocker to knock a flat surface of the conical table. The knocker generates the low frequency wave with a predetermined frequency.
Owner:TAIWAN OASIS TECH CO LTD

Information analysis system for evaluating stereotactic intracerebral transplantation curative effect of endothelial progenitor cells

The invention relates to the technical field of biomedicine and information, and discloses an information analysis system for evaluating the stereotactic intracerebral transplantation curative effect of endothelial progenitor cells, which comprises a multi-channel sensor array, a data acquisition module, a data processing module and a feedback output module, the multi-channel sensor array is composed of a plurality of miniature sensor units, each sensor unit comprises an optical probe, an electrochemical detection electrode and an ultrasonic transmitting and receiving device, and the sensor units are used for collecting physiological signals, chemical signals and image signals of a brain operation area in real time; and the data acquisition module is connected with the multi-channel sensor array. Signals of a brain operation area are collected in real time through the multi-channel sensor array, synchronous collection of the data collection module and dynamic analysis of the data processing module are combined, and the survival state, the distribution condition and the function change of transplanted endothelial progenitor cells can be monitored in real time.
Owner:GUIZHOU MEDICAL UNIV

Adult stem cell compositions and methods of identification and isolation

PendingUS20260071178A1Cell differentiationBiological material analysisProgenitorTruncated receptor
Methods, compositions and cells are provided that identify and isolate a population of adult non-embryonic progenitor cells having multilineage potential, physical diameters of about 2 μm to about 8 μm in size or about 4 μm to about 6 μm, and expressing at least one of the stem cell associated genes among Oct-4, KLF-4, Nanog, Sox-2, Rex-1, GDF-3 or Stella. Methods are also provided that identify and isolate populations, which are subsets or subpopulations of progenitor adult stem cells within the population of the adult stem cells which is a heterogeneous population, the methods including contacting the adult stem cells with a ligand specific for at least one of: CD99, tetraspan, ICAM4, full-length MUC1, and truncated MUC1 receptor, in which a presence of a surface protein on the cells that bind to the ligand identifies the population which is the subset of the differentiated progenitor adult stem cells.
Owner:TACS BIO INC